logo
  

Roche & Atea Join To Develop AT-527 As Treatment For COVID-19 Patients

Roche (RHHBY) and Atea Pharmaceuticals, Inc. have agreed to collaborate to develop, manufacture and distribute AT-527, Atea's investigational oral direct-acting antiviral, as a potential oral treatment for COVID-19 patients. If approved, Atea will distribute AT-527 in the United States and Roche will be responsible for global manufacturing and distribution outside the United States.

AT-527 is an investigational, oral, purine nucleotide prodrug, which has demonstrated in vitro and in vivo antiviral activity against several enveloped single-stranded RNA viruses, including human flaviviruses and coronaviruses.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Green Field Farms Dairy has recalled its Whole Chocolate Milk product as a laboratory analysis indicated that the product was not effectively pasteurized, the U.S. Food and Drug Administration announced. The recall involves 1,242 units of the Whole Chocolate Milk with an expiration date of September 29, 2021. General Motors will start replacing defective battery modules in Chevrolet Bolt EVs and EUVs with new modules. The replacement battery modules will be shipped to dealers as soon as mid-October, the automaker said in a statement. CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing.
Follow RTT